Shanghai-based biotechnology company Revvity has entered into a comprehensive partnership with Sanyou Biopharmaceuticals Co., Ltd to enhance the development of innovative biologic drugs. The two companies have signed a commercial licensing agreement that will see Sanyou incorporate the TnT transposon system into the CHOSOURCE protein expression platform. Financial details of the agreement were not disclosed.
Sanyou had previously licensed the commercialization rights for two of Revvity’s GS knockout CHO K1 cell lines, further solidifying their collaboration in the biologics space.
The integration of CHOSORCE TnT transposon technology with CHOSORCE GS KO cell lines is expected to offer numerous benefits. It significantly streamlines development timelines by ensuring rapid recovery during cell pool selection and maintaining high consistency between pools and clones. This high level of repeatability minimizes the need for extensive screening of multiple cell pools and/or clones, thereby simplifying the overall process of cell line development.- Flcube.com
